See more : MEDirect Latino, Inc. (MLTO) Income Statement Analysis – Financial Results
Complete financial analysis of DermTech, Inc. (DMTK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of DermTech, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
You may be interested
- Sunwah Kingsway Capital Holdings Limited (0188.HK) Income Statement Analysis – Financial Results
- Affinity Gold Corporation (AFYG) Income Statement Analysis – Financial Results
- Golub Capital BDC, Inc. (GBDC) Income Statement Analysis – Financial Results
- Narmada Agrobase Limited (NARMADA.BO) Income Statement Analysis – Financial Results
- Jindal Drilling & Industries Limited (JINDRILL.NS) Income Statement Analysis – Financial Results
DermTech, Inc. (DMTK)
About DermTech, Inc.
DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. It offers DermTech Melanoma Test (DMT), a gene expression test that enhances early detection of genomic atypia and helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. The company also provides adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. In addition, it is developing UV damage DNA risk assessment products, as well as non-melanoma skin cancer diagnostic and cutaneous T-cell lymphoma rule out test products, as well as offering health-related and information services through electronic information and telecommunication technologies. The company sells its products primarily to pathology and oncology practitioners. DermTech, Inc. is headquartered in La Jolla, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 15.30M | 14.52M | 11.84M | 5.89M | 3.36M | 0.00 | 0.00 |
| Cost of Revenue | 15.02M | 13.87M | 10.56M | 5.98M | 3.30M | 306.24K | 0.00 |
| Gross Profit | 276.00K | 647.00K | 1.27M | -96.00K | 60.00K | -306.24K | 0.00 |
| Gross Profit Ratio | 1.80% | 4.46% | 10.76% | -1.63% | 1.78% | 0.00% | 0.00% |
| Research & Development | 15.24M | 24.05M | 16.26M | 5.29M | 2.50M | 0.00 | 0.00 |
| General & Administrative | 43.78M | 36.09M | 24.84M | 13.82M | 8.87M | 0.00 | 0.00 |
| Selling & Marketing | 45.00M | 58.67M | 37.58M | 16.08M | 6.30M | 0.00 | 0.00 |
| SG&A | 88.78M | 94.76M | 62.41M | 29.90M | 15.17M | 0.00 | 0.00 |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | -355.00K | 306.24K | 60.00 |
| Operating Expenses | 104.02M | 118.81M | 78.67M | 35.19M | 17.67M | 306.24K | 60.00 |
| Cost & Expenses | 119.04M | 132.68M | 89.24M | 41.17M | 20.97M | 306.24K | 60.00 |
| Interest Income | 2.85M | 1.34M | 151.00K | 40.00K | 0.00 | 1.09M | 0.00 |
| Interest Expense | 0.00 | 1.34M | 0.00 | 40.00K | 2.66M | 0.00 | 0.00 |
| Depreciation & Amortization | 5.85M | -141.00K | 1.09M | 486.00K | -355.00K | 45.42K | 52.52K |
| EBITDA | -97.89M | -118.31M | -76.31M | -35.29M | -17.96M | -260.83K | -60.00 |
| EBITDA Ratio | -639.99% | -814.89% | -644.62% | -599.64% | -533.89% | 0.00% | 0.00% |
| Operating Income | -103.74M | -118.17M | -77.40M | -35.29M | -17.61M | -306.24K | -60.00 |
| Operating Income Ratio | -678.21% | -813.92% | -653.81% | -599.64% | -523.34% | 0.00% | 0.00% |
| Total Other Income/Expenses | 2.85M | 1.48M | -937.00K | -1.19M | -2.08M | 1.56M | 306.18K |
| Income Before Tax | -100.89M | -116.68M | -78.34M | -35.25M | -19.69M | 856.41K | -60.00 |
| Income Before Tax Ratio | -659.57% | -803.71% | -661.72% | -598.96% | -585.29% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -2.96M | -1.36M | -526.00K | 2.21M | -1.16M | 0.00 |
| Net Income | -100.89M | -113.72M | -76.98M | -34.72M | -21.90M | 856.41K | -60.00 |
| Net Income Ratio | -659.57% | -783.30% | -650.24% | -590.03% | -651.07% | 0.00% | 0.00% |
| EPS | -3.09 | -3.79 | -2.66 | -2.05 | -3.13 | 0.36 | 0.00 |
| EPS Diluted | -3.09 | -3.79 | -2.66 | -2.05 | -3.13 | 0.36 | 0.00 |
| Weighted Avg Shares Out | 32.64M | 30.04M | 28.88M | 16.98M | 7.01M | 2.36M | 1.82M |
| Weighted Avg Shares Out (Dil) | 32.64M | 30.04M | 28.88M | 16.98M | 7.01M | 2.36M | 8.07M |
DMTK Investors Have Opportunity to Lead DermTech, Inc. Securities Fraud Lawsuit
LOS ANGELES , Nov. 27, 2023 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against DermTech, Inc. ("DermTech" or the "Company") (NASDAQ: DMTK). Class...
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind DermTech Investors of a Lead Plaintiff Deadline of December 15, 2023
NEW YORK , Nov. 27, 2023 /PRNewswire/ -- Attention DermTech, Inc. ("DermTech") (NASDAQ: DMTK) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between May 3, 2022 and...
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages DermTech, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - DMTK
NEW YORK , Nov. 26, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of DermTech, Inc. (NASDAQ: DMTK) between May 3, 2022 and November 3, 2022, both dates inclusive (the "Class Period"), of...
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in DermTech, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / November 24, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against DermTech, Inc. ("DermTech" or "the Company") (NASDAQ:DMTK) for violations of §§10(b) and...
DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in DermTech, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / November 23, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against DermTech, Inc. ("DermTech" or "the Company") (NASDAQ:DMTK) for violations of §§10(b) and...
DMTK Investors Have Opportunity to Lead DermTech, Inc. Securities Fraud Lawsuit
LOS ANGELES , Nov. 22, 2023 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against DermTech, Inc. ("DermTech" or the "Company") (NASDAQ: DMTK).
DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in DermTech, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / November 22, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against DermTech, Inc. ("DermTech" or "the Company") (NASDAQ:DMTK) for violations of 10(b) and...
DMTK INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that DermTech, Inc. Investors with Substantial Losses Have Opportunity to Lead Case
SAN DIEGO--(BUSINESS WIRE)--The suit alleges defendants issued false statements concerning DermTech business and prospects, resulting in its stock trading at inflated prices.
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of DermTech, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of December 15, 2023 - (NASDAQ: DMTK)
NEW YORK , Nov. 21, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of DermTech, Inc.. Shareholders who purchased shares of DMTK during the class period listed are encouraged to contact the firm regarding possible...
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in DermTech, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / November 21, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against DermTech, Inc. ("DermTech" or "the Company") (NASDAQ:DMTK) for violations of §§10(b) and...
Source: https://incomestatements.info
Category: Stock Reports